FDA approves Sun Pharma’s JAK inhibitor for alopecia
The FDA approval is based on data gathered from two Phase III studies where over 30% of the patients gained 80% or more coverage of scalp hair.
Approvals
EC conditionally approves Pfizer’s haemophilia B gene therapy
FDA agrees wider use of BioMarin’s BRINEURA for CLN2
NICE recommends Boehringer’s tenecteplase for NHS stroke care
MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine
MHRA approves Novo Nordisk’s semaglutide to cut cardiovascular risk
FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar
UK MHRA approves Lupin and Zentiva’s raltegravir for HIV
